Free Trial
OTCMKTS:YBGJ

Yubo International Biotech (YBGJ) Stock Price, News & Analysis

$0.05 0.00 (-0.60%)
(As of 12/20/2024 05:55 PM ET)

About Yubo International Biotech Stock (OTCMKTS:YBGJ)

Key Stats

Today's Range
$0.05
$0.05
50-Day Range
$0.03
$0.13
52-Week Range
$0.03
$1.37
Volume
1,000 shs
Average Volume
111,478 shs
Market Capitalization
$5.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Yubo International Biotech Limited, through its subsidiaries, focuses on the research and development, and application of endometrial stem cells. It offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. The company is headquartered in Beijing, China.

Yubo International Biotech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
7th Percentile Overall Score

YBGJ MarketRank™: 

Yubo International Biotech scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Yubo International Biotech.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Yubo International Biotech is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Yubo International Biotech is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Yubo International Biotech have been sold short.
  • Short Interest Ratio / Days to Cover

    Yubo International Biotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Yubo International Biotech does not currently pay a dividend.

  • Dividend Growth

    Yubo International Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Yubo International Biotech have been sold short.
  • Short Interest Ratio / Days to Cover

    Yubo International Biotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    Yubo International Biotech has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Yubo International Biotech this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    3 people have added Yubo International Biotech to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Yubo International Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    56.48% of the stock of Yubo International Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Yubo International Biotech's insider trading history.
Receive YBGJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yubo International Biotech and its competitors with MarketBeat's FREE daily newsletter.

YBGJ Stock News Headlines

Yubo International Biotech (YBGJ) versus Its Rivals Head-To-Head Contrast
Comparing Yubo International Biotech (YBGJ) and Its Peers
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Yubo International Biotech (YBGJ) and Its Rivals Critical Review
Yubo International Biotech (YBGJ) and Its Rivals Financial Review
See More Headlines

YBGJ Stock Analysis - Frequently Asked Questions

Yubo International Biotech's stock was trading at $0.30 at the start of the year. Since then, YBGJ shares have decreased by 83.4% and is now trading at $0.0497.
View the best growth stocks for 2024 here
.

Shares of YBGJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Yubo International Biotech investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Bank of America (BAC).

Company Calendar

Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:YBGJ
Employees
20
Year Founded
N/A

Profitability

Net Income
$-1,200,000.00
Net Margins
-274.96%
Pretax Margin
-8,254.97%

Debt

Sales & Book Value

Annual Sales
$610,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$5.87 million
Optionable
Not Optionable
Beta
2.99
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (OTCMKTS:YBGJ) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners